Royalty Pharma plc (RPRX)

Market Cap	19.00B
Revenue (ttm)	2.26B
Net Income (ttm)	859.00M
Shares Out	587.43M
EPS (ttm)	1.45
PE Ratio	22.36
Forward PE	6.73
Dividend	$0.88 (2.72%)
Ex-Dividend Date	Feb 21, 2025

Volume	3,662,225
Open	32.27
Previous Close	32.25
Day's Range	31.73 - 32.56
52-Week Range	24.05 - 32.72
Beta	0.49
Analysts	Strong Buy
Price Target	41.67 (+28.85%)
Earnings Date	Feb 11, 2025

About RPRX

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 16, 2020
• Employees: 89
• Stock Exchange: NASDAQ
• Ticker Symbol: RPRX
• Website: https://www.royaltypharma.com

Financial Performance

In 2024, Royalty Pharma's revenue was $2.26 billion, a decrease of -3.89% compared to the previous year's $2.35 billion. Earnings were $859.00 million, a decrease of -24.31%.

Analyst Forecast

According to 6 analysts, the average rating for RPRX stock is "Strong Buy." The 12-month stock price forecast is $41.67, which is an increase of 28.85% from the latest price.

Price Target

$41.67

(28.85% upside)

Analyst Consensus: Strong Buy